Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) fell 4.8% during mid-day trading on Wednesday . The company traded as low as $15.04 and last traded at $15.04. 235,997 shares were traded during mid-day trading, a decline of 74% from the average session volume of 909,716 shares. The stock had previously closed at $15.80.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on CAPR. Cantor Fitzgerald increased their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. HC Wainwright restated a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $34.50.
Read Our Latest Stock Analysis on CAPR
Capricor Therapeutics Price Performance
The firm has a market capitalization of $699.33 million, a price-to-earnings ratio of -14.51 and a beta of 4.08. The firm has a 50 day moving average price of $14.42 and a 200-day moving average price of $13.73.
Institutional Trading of Capricor Therapeutics
Several hedge funds have recently modified their holdings of the stock. Oppenheimer & Co. Inc. raised its stake in Capricor Therapeutics by 25.2% in the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company's stock valued at $1,040,000 after buying an additional 13,762 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Capricor Therapeutics in the third quarter valued at $161,000. FMR LLC acquired a new stake in Capricor Therapeutics in the third quarter valued at $370,000. BNP Paribas Financial Markets raised its stake in Capricor Therapeutics by 868.7% in the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company's stock valued at $269,000 after buying an additional 15,872 shares in the last quarter. Finally, Fred Alger Management LLC acquired a new stake in Capricor Therapeutics in the third quarter valued at $399,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
